Меню
Набор скоро начнётся NCT07332715

Predictive Value of the Uric Acid/Albumin Ratio and Lactate in Sepsis Patients

— Наблюдательное Sepsis-Related Mortality Acute Kidney Injury

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Non-interventional / Observational Study.
Кому может быть актуально
Состояния в реестре: Sepsis-Related Mortality, Acute Kidney Injury. Базовые параметры: от 65 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Turkey (Türkiye)
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Predictive Value of the Combination of Uric Acid/Albumin Ratio and Lactate for Acute Kidney Injury, Hemodynamic Support Requirement, and Mortality in Patients With Sepsis

Обзор

Sepsis is a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection and remains a leading cause of morbidity and mortality in intensive care units. Early identification of patients at high risk for adverse outcomes is essential for timely intervention and improved prognosis. This prospective, single-center, non-interventional study aims to evaluate the predictive value of the combined use of the blood uric acid/albumin ratio (UAR) and serum lactate levels in patients aged 65 years and older who are admitted to the intensive care unit with a diagnosis of sepsis according to SEPSIS-3 criteria. Patients without acute kidney injury at admission and with at least 24 hours of intensive care follow-up will be included. The primary outcome is the development of acute kidney injury within the first 7 days of ICU admission according to KDIGO criteria. Secondary outcomes include vasopressor requirement during ICU stay, changes in serum lactate levels over the first 24 hours, and 28-day mortality. The study seeks to determine whether the combination of UAR and lactate levels can serve as an easily accessible and clinically applicable biomarker to predict adverse outcomes and support prognostic assessment and treatment strategies in sepsis patients.

Вмешательства

  • Другое Non-interventional / Observational Study
    This is a non-interventional, observational study. No diagnostic or therapeutic intervention will be applied beyond routine clinical care. Blood uric acid, albumin, and serum lactate levels measured as part of standard intensive care management will be recorded at admission, and lactate levels will be reassessed at 24 hours. Patients will be followed prospectively during their intensive care stay to evaluate the development of acute kidney injury, vasopressor requirement, and 28-day mortality.

Первичные конечные точки

  • Development of Acute Kidney Injury (AKI) [Срок оценки: Within the first 7 days following intensive care unit admission]

Критерии участия

Критерии включения

  • Patients aged 65 years and older
  • Diagnosis of sepsis according to SEPSIS-3 criteria
  • Admission to the intensive care unit
  • No acute kidney injury at admission according to KDIGO classification
  • Measurement of serum uric acid, albumin, and lactate levels at ICU admission
  • SOFA score calculated at ICU admission
  • ICU follow-up of at least 24 hours

Критерии исключения

  • Age under 65 years
  • Uncompensated or decompensated chronic liver disease (e.g., Child-Pugh class C)
  • Chronic kidney disease stage 4 or 5 (eGFR <30 mL/min/1.73 m²)
  • Presence of acute kidney injury at admission according to KDIGO criteria
  • Active malignancy or receipt of active cancer treatment within the last 6 months
  • Missing or incomplete clinical/laboratory data
  • ICU follow-up less than 24 hours

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

Turkey (Türkiye) · 1 центр
  • Istinye Üniversity — Istanbul

Публикации

  • Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287. PMID 26903338
  • Barichello T, Generoso JS, Singer M, Dal-Pizzol F. Biomarkers for sepsis: more than just fever and leukocytosis-a narrative review. Crit Care. 2022 Jan 6;26(1):14. doi: 10.1186/s13054-021-03862-5. PMID 34991675

Идентификаторы

NCT: NCT07332715 · 330-2025

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗